---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-018465"
form_type: "8-K"
ticker: "ACLX"
cik: "0001786205"
company_name: "Arcellx, Inc."
filed_at: "2023-01-30T23:59:59+00:00"
generated_at: "2026-06-20T06:43:44.412062+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arcellx closes collaboration with Kite/Gilead for CART-ddBCMA; sells $100M of stock to Gilead

## Summary
- Global collaboration to co-develop and co-commercialize CART-ddBCMA for relapsed/refractory multiple myeloma.
- CART-ddBCMA is in Phase 2 pivotal trial; companies will co-commercialize in U.S., Kite outside U.S.
- Arcellx sold 3,478,261 shares of common stock to Gilead for aggregate ~$100M.
- Closing followed expiration of HSR waiting period; deal previously disclosed in December 2022.

## SEC filing metadata
- accession: 0001193125-23-018465
- form_type: 8-K
- ticker: ACLX
- cik: 0001786205
- company_name: Arcellx, Inc.
- filed_at: 2023-01-30T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1786205/000119312523018465/0001193125-23-018465-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1786205/000119312523018465/d434551d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-018465
- JSON: https://secwatch.observer/filing/0001193125-23-018465.json
- Plain text: https://secwatch.observer/filing/0001193125-23-018465.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.